Betamethasone Dipropionate 0.05%

Introduction Overview

Generic Name

betamethasone dipropionate 0.05%

Brand Name

Sernivo

Dosage Form

topical spray

Drug Class

Topical steroids

Pharmacokinetics

Absorption:
Betamethasone dipropionate in Sernivo Spray, as a topical corticosteroid, is absorbed through the epidermal and dermal layers of the skin. Its absorption rate is influenced by the thickness and integrity of the skin, the presence of inflammation or disease (such as psoriasis), and the use of occlusive dressings. Due to the increased lipophilicity afforded by its dual ester structure, betamethasone dipropionate exhibits enhanced penetration through the stratum corneum compared to single ester corticosteroids. Clinical use is limited to a maximum of four consecutive weeks primarily due to systemic absorption concerns, as prolonged exposure can increase systemic bioavailability.

Distribution:
Following skin absorption, betamethasone dipropionate distributes locally within the skin tissues exerting anti-inflammatory effects. Systemic distribution is minimal if used as directed, but when absorbed, the drug binds extensively to plasma proteins, primarily albumin, facilitating distribution throughout systemic circulation. Due to its lipophilic nature, it preferentially localizes in fatty tissues. The topical route limits systemic exposure; however, in cases of extensive skin application, damaged skin, or use under occlusion, increased systemic distribution may occur, potentially leading to hypothalamic-pituitary-adrenal (HPA) axis suppression.

Metabolism:
Betamethasone dipropionate undergoes extensive metabolism primarily via hydrolysis of its ester moieties, converting it into betamethasone 17-propionate and then to betamethasone. These metabolites retain glucocorticoid activity but at reduced potency compared to the parent compound. Metabolic processing primarily occurs in the skin and liver, with the skin initiating ester hydrolysis directly. Hepatic metabolism involves further conjugation reactions facilitating elimination. The high first-pass metabolism limits systemic effects; however, sufficient absorption can still impact systemic corticosteroid levels.

Elimination:
Elimination of betamethasone dipropionate and its metabolites occurs predominantly through renal excretion of glucuronide and sulfate conjugates. Small amounts may be eliminated in bile and feces. The elimination half-life is variable depending on the extent of systemic absorption but is generally short following topical administration. Clinically, the elimination profile supports once or twice daily application. Caution is advised with prolonged use or application over large skin areas to avoid accumulation and systemic corticosteroid-related adverse effects.

Dosage Forms

Available Dosage Forms:
Sernivo is formulated as a topical spray intended for cutaneous application. The product is supplied as a spray containing 0.05% betamethasone dipropionate in a non-augmented cream-like preparation. It is available in 60 mL and 120 mL polyethylene bottles equipped with a manual spray pump for accurate dosing and ease of topical application.

Dosages for Adults and Adolescents:
The recommended dosing regimen for adults (ages 18 and older) with mild to moderate plaque psoriasis is to apply Sernivo Spray twice daily directly to the affected skin areas. Application involves spraying onto lesions followed by gentle rubbing to facilitate absorption. Treatment duration should not exceed 4 consecutive weeks. If psoriasis does not improve after 2 weeks of therapy, discontinuation and medical reassessment are advised.

Specific Patient Populations:
Sernivo Spray is contraindicated in pediatric patients under 18 years due to increased risk of systemic corticosteroid effects. Its safety during pregnancy and breastfeeding is not fully established; therefore, use should be limited to situations where expected benefits outweigh potential risks, with minimal exposure and avoidance of application on the breasts during lactation. The product should be avoided on thin skin areas such as the face, groin, axillae, and skin folds to minimize local adverse effects.

Mechanism Of Action

Betamethasone dipropionate, the active component of Sernivo Spray, exerts its therapeutic effects primarily through potent anti-inflammatory and immunosuppressive actions mediated via glucocorticoid receptor binding. Upon topical application, betamethasone diffuses into skin cells where it binds to intracellular glucocorticoid receptors, forming a drug-receptor complex that translocates to the nucleus. This complex modulates gene expression by upregulating anti-inflammatory proteins (such as lipocortin-1, which inhibits phospholipase A2) and downregulating pro-inflammatory mediators including cytokines, chemokines, and enzymes responsible for prostaglandin and leukotriene synthesis.

This molecular modulation results in inhibition of key inflammatory pathways, reducing vasodilation, capillary permeability, and recruitment of inflammatory cells to psoriatic plaques. Concurrently, betamethasone dipropionate suppresses cellular immune responses by decreasing the proliferation and activation of T lymphocytes and other immune cells implicated in the pathogenesis of psoriasis, thereby mitigating epidermal hyperproliferation and inflammatory lesion formation.

Unlike some corticosteroids augmented with penetration enhancers, Sernivo Spray is a non-augmented formulation which, combined with its unique dipropionate ester structure, achieves an optimal balance between potent skin penetration and controlled systemic absorption. This mechanism provides effective symptom relief with a relatively reduced risk of systemic glucocorticoid adverse effects.

Comparatively, betamethasone dipropionate exhibits greater potency and efficacy than monoester corticosteroids such as betamethasone valerate due to enhanced lipophilicity and skin bioavailability. Clinical trials have demonstrated significant clearance of psoriatic plaques and improvement of inflammation within 4 weeks of twice-daily application, affirming its mechanism's effectiveness in topical dermatologic therapy.

Pharmacological Actions

Potent anti-inflammatory activity reducing skin inflammation associated with plaque psoriasis.
Immunosuppressive effects attenuating local immune-mediated processes in psoriatic lesions.
Vasoconstrictive properties leading to decreased capillary permeability and redness.
Inhibition of phospholipase A2, thereby blocking arachidonic acid cascade and prostaglandin synthesis.
Suppression of cytokine and chemokine production diminishing leukocyte recruitment.
Reduction in T cell activation and proliferation in affected skin.
Mitigation of epidermal hyperproliferation characteristic of psoriasis plaques.
Local analgesic effect by reducing inflammatory mediators involved in itching and pain.
Minimal systemic exposure when used as directed, limiting systemic corticosteroid effects.
Non-augmentation formulation to balance potency with safety in topical corticosteroid therapy.
Topical glucocorticoid class providing targeted dermatological treatment.

Therapeutic Or Clinical Uses

Treatment of mild to moderate plaque psoriasis in adults aged 18 years and older.
Reduction of inflammation, scaling, and itching associated with psoriatic plaques.
Short-term (up to 4 weeks) management of localized dermatologic inflammatory skin disorders.
Symptomatic relief of pruritus associated with chronic plaque psoriasis.
Topical corticosteroid option for patients requiring moderate to high potency agent without augmentation.
Alternate therapy for patients intolerant to other topical corticosteroids due to formulation differences.
Adjunctive treatment to systemic or biologic therapies for controlled plaque psoriasis.
Management of psoriatic plaques on elbows, knees, and other accessible body areas.
Off-label use may include other corticosteroid-responsive dermatoses under medical supervision.
Suitable for patients needing a spray formulation to ease application over large or difficult-to-reach skin areas.

Side Or Adverse Effects

Local itching, burning, stinging, or pain at the application site.
Skin atrophy (thinning) resulting from prolonged topical corticosteroid use.
Dryness, cracking, or peeling of the treated skin.
Allergic contact dermatitis presenting as redness, rash, or hives.
Development of acneiform eruptions or worsening of existing acne.
Telangiectasia (spider veins) due to dermal capillary fragility.
Stretch marks (striae) developing after extended application.
Hypothalamic-pituitary-adrenal (HPA) axis suppression with excessive or prolonged use.
Systemic corticosteroid effects such as Cushing’s syndrome, hyperglycemia, and glucosuria if absorbed in significant amounts.
Possible secondary skin infections due to local immunosuppression.
Facial and body weight gain, increased body hair growth, mood changes indicative of systemic corticosteroid exposure.
Menstrual irregularities and sexual dysfunction related to systemic absorption.
Ocular effects like increased intraocular pressure if used near eyes inappropriately.
Skin pigmentation changes in long-term treatment areas.
Rare occurrence of hypersensitivity reactions necessitating discontinuation.

Precautions

Do not use Sernivo Spray longer than 4 consecutive weeks to avoid systemic absorption risks.
Avoid application on thin skin areas such as face, groin, axillae, and skin folds.
Avoid occlusive dressings unless specifically advised by a healthcare provider due to increased absorption risk.
Do not use other corticosteroid products concomitantly to prevent additive systemic effects.
Use caution in patients with diabetes as topical corticosteroids may increase blood glucose levels.
Avoid use in patients with known hypersensitivity to betamethasone dipropionate or any inactive ingredients.
Discontinue therapy if no improvement is seen after 2 weeks and seek further medical advice.
Not recommended for use in children or adolescents under 18 due to increased susceptibility to systemic corticosteroid side effects.
Use with caution in patients with a history of skin infections or liver disease.
Monitor patients for signs of HPA axis suppression, especially if applied over large skin areas or under occlusion.
Pregnant and breastfeeding women should use only minimal amounts if the potential benefit justifies the risk.
Avoid application to damaged or infected skin unless directed by a physician.
Wash hands after application unless treating hand lesions to prevent inadvertent ocular or mucous membrane exposure.
Inform healthcare providers of all concomitant medications to avoid potential interactions.
Store at room temperature and avoid freezing to maintain product stability.

Warnings

Do not exceed recommended dosing or apply for longer than 4 consecutive weeks to prevent systemic corticosteroid side effects.
Use care when applying on large areas of skin to minimize systemic absorption risk.
Avoid occlusive dressings without medical supervision as they increase the likelihood of adverse effects.
Potential for reversible hypothalamic-pituitary-adrenal (HPA) axis suppression which can lead to glucocorticoid insufficiency.
Signs of systemic absorption include Cushing’s syndrome symptoms, hyperglycemia, and glucosuria; monitor accordingly.
Discontinue use immediately if signs of allergic reaction or skin irritation occur.
Not for oral, ocular, or mucous membrane application; avoid contact with eyes.
Use not recommended in children and adolescents under 18 years due to heightened side effect risk.
Pregnant or breastfeeding women must use caution and only under physician guidance.
Do not use on face, scalp, underarms, groin, or skin folds to prevent local steroid-related complications.
Avoid concurrent use of other topical or systemic corticosteroids to lower additive systemic exposure.
Keep out of reach of children to prevent accidental ingestion or misuse.
If psoriasis worsens or new lesions appear, discontinue and consult a healthcare provider.
Storage conditions should be adhered to for maintaining efficacy and safety.
Report any unusual systemic or local side effects promptly to a healthcare professional.

Contraindication

Known hypersensitivity or allergy to betamethasone dipropionate or any component of the formulation.
Presence of untreated bacterial, viral, fungal, or parasitic skin infections at the intended site of application.
Use on thin skin areas such as face, scalp, groin, axillae, and skin folds due to increased risk of atrophy.
Use in children and adolescents under 18 years of age due to susceptibility to systemic effects.
Do not apply over mucous membranes or to eyes.
Patients with a history of corticosteroid-induced skin reactions or thinning.
Patients with active skin ulcers or atrophic skin conditions contraindicated for potent corticosteroid use.
Known adrenal gland disorders where corticosteroid use may exacerbate hormonal imbalances.
Use in breastfeeding women over areas where infant suckling may occur unless specifically advised.
Concurrent use with other topical corticosteroids unless directed by a healthcare provider.
Use in patients with glaucoma or cataracts unless under close medical supervision.
Any prior severe adverse reaction to topical corticosteroids.
Do not apply to skin areas with untreated psoriasis infections without adjunctive therapy.
Contraindicated if occlusive dressings are planned without healthcare provider approval.
Known liver disease patients should use caution due to altered corticosteroid metabolism.

Drug Interactions

Concurrent use with other topical corticosteroids may result in additive systemic or local corticosteroid effects.
Co-administration with systemic corticosteroids can increase the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression.
Use with immunosuppressive agents could potentiate immunosuppression increasing infection risk.
Interactions with antidiabetic medications may occur, as topical corticosteroids can elevate blood glucose levels.
Concurrent use with anticoagulants may alter bleeding risk, indirect via systemic corticosteroid effects.
Potential interaction with vaccines, possibly diminishing immunogenic response when corticosteroids are systemically absorbed.
Use caution with cytochrome P450 enzyme inducers or inhibitors that may alter systemic corticosteroid metabolism if absorption is significant.
Avoid concomitant use with topical irritants or sensitizers that may increase skin permeability and systemic absorption.
No significant interactions expected with non-systemic medications due to minimal systemic bioavailability.
Monitoring required if used alongside antiepileptics as systemic corticosteroids may lower seizure threshold.
Co-application with topical antifungals or antibacterials advisable only under professional guidance.
Herbal supplements with immunomodulatory properties should be disclosed to healthcare providers to avoid unintended interactions.
Careful monitoring advised if patient is on psychotropic agents as corticosteroids may influence mood and behavior.
Inform healthcare providers of all medications to ensure comprehensive interaction assessment.
Spreading or enhancement of systemic corticosteroid adverse effects possible when other corticosteroid formulations are added.

Preparations Of The Drug

Sernivo Spray containing 0.05% betamethasone dipropionate formulated as a non-augmented topical spray.
Available in 60 mL and 120 mL polyethylene spray bottles with manual spray pump for precise application.
Contains inactive ingredients such as butylated hydroxytoluene, cetostearyl alcohol, hydroxyethyl cellulose, methylparaben, mineral oil, oleyl alcohol, polyoxyl 20 cetostearyl ether, propylparaben, purified water, and sorbitan monostearate.
Supplied with a pharmacist-installed manual spray pump to ensure proper dosing delivery.
Formulated to deliver a lotion-like feel despite being a spray, improving patient compliance.
Non-augmented formulation differentiates it from other betamethasone dipropionate products containing penetration enhancers like propylene glycol.
Manufactured by Primus Pharmaceuticals, Inc., ensuring compliance with FDA regulation and quality control standards.
Stored at room temperature (20°C to 25°C) with instructions to avoid freezing to preserve drug stability.
Packaged to minimize contamination risk and maintain topical corticosteroid potency.
Designed for dermatologic use only, with instructions emphasizing avoidance of mucous membranes and eyes.
Presentation supports treatment of large or difficult-to-reach areas due to its spray format.
Includes clear labeling on usage duration and maximum treatment period to prevent misuse.
Available only by prescription, emphasizing the need for medical supervision during treatment.
No oral or injectable formulations of Sernivo; strictly topical use.
Packaging incorporates patient information leaflets detailing indications, warnings, and application instructions.